Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 5/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2017786 | 0.87 | ESR2 (0.36) | MIFEGFRKDM4ENR1H2 | |
| SCHEMBL2016038 | 0.85 | GRIN2D (0.38) | — | |
| SCHEMBL3746526 | 0.81 | ITGB3 (0.35) | KDM4E | |
| SCHEMBL21028027 | 0.81 | KMT2A (0.37) | KDM4ESMN1; SMN2 | |
| SCHEMBL3424640 | 0.72 | CCR9 (0.39) | KDM4ENR1H2 | |
| SCHEMBL2019619 | 0.71 | YAP1 (0.41) | FFAR1 | |
| SCHEMBL2018071 | 0.68 | HSD17B1 (0.35) | MIFEGFRKDM4EHSD17B1 | |
| SCHEMBL28519462 | 0.68 | GPR119 (0.46) | — | |
| SCHEMBL2016667 | 0.67 | LMNA (0.38) | KDM4E | |
| SCHEMBL2446506 | 0.67 | S1PR1 (0.46) | MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542554-B1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARM INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20150284399-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-9085581-B2 | Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof | ARENA PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| EP-2542554-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2013-01-09 | — | — | EP | disclosed |
| US-20120329848-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2011109471-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329848-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | S1PR1, S1PR5, S1PR2 | MIF 220/4885HDAC6 3301/4885EGFR 679/4885 |
| US-20150284399-A1 | PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF | S1PR1, S1PR5, S1PR2 | MIF 238/4885HDAC6 3343/4885EGFR 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.